Loop Gain (LG), a concept borrowed from engineering used to describe the stability of electrical circuits under negative feedback, has emerged as a crucial pathophysiological trait in sleep respiratory disorders. In simple terms, LG measures how the respiratory control system reacts to changes in breathing. A high LG suggests that minor disturbances in breathing prompt exaggerated responses, potentially leading to instability and oscillations in respiratory patterns. Conversely, a low LG implies that the system responds more gently to disturbances, resulting in stable and well-regulated breathing. However, understanding the concept of loop gain presents challenges due to its dynamic nature across various sleep respiratory disorders, sleep stages, positions, and interactions with other pathophysiological traits. Recent efforts have aimed to identify a non-invasive method for assessing LG, with some evidence suggesting that information regarding pathophysiological traits can be extracted from polysomnography. There exists a clinical imperative for physician to unravel the intricacies of LG when managing Obstructive Sleep Apnea (OSA) patients, because LG abnormalities delineate a distinct pathophysiological phenotype of OSA. Specifically, certain patients exhibit a high LG as the primary factor driving sleep apnea, influencing treatment outcomes. For instance, individuals with high LG may respond differently to therapies such as continuous positive airway pressure (CPAP) or oral appliances compared to those with normal LG, or they can be treated with specific drugs or combination therapies. Thus, understanding LG becomes paramount for precise assessment of OSA patients and is fundamental for optimizing a personalized and effective treatment approach.
Systemic sclerosis (SSc) patients are often affected by interstitial lung disease (ILD) and, although there have been recent treatment advances, it remains the leading cause of death among SSc, with a 10-year mortality up to 40%. African Americans and subjects with diffuse cutaneous SSc or anti-topoisomerase 1 antibodies are most commonly affected. Currently, early ILD diagnosis can be made, and it is pivotal to improve the prognosis. The diagnostic mainstay test for SSc-ILD is high-resolution computed tomography for the morphology and pulmonary function tests for the functional aspects. Treatment planning and intensity are guided by the disease severity and risk of progression. Traditionally, therapy has depended on combinations of immunosuppressants, particularly cyclophosphamide and mycophenolate mofetil, which can be supplemented by targeted biological and antifibrotic therapies. Benefits have been observed in trials on hematopoietic autologous stem cell transplantation for patients with progressive SSc, whilst lung transplantation is reserved for refractory SSc-ILD cases. Herein, recent advances in SSc-ILD treatment will be explored.
Obstructive Sleep Apnea Syndrome (OSAS) is the most common sleep-related breathing disorder, considered more prevalent in males. Recent evidences suggest that prevalence of OSAS in females is underestimated, with a clinical phenotype marked by sleep fragmentation, poor sleep quality, and neurobehavioral symptoms. We hypothesized that a low arousal threshold (low AT) may be more common in females, which may underline these clinical and polysomnographic differences. In this retrospective multicentric study, 84 females and 93 males with OSA underwent a Home Sleep Apnea Test (HSAT) reviewed by a sleep expert. Low AT was predicted using the Edwards score criteria. Out of 177 patients, low AT was identified in 60.7 % of females and 40.9 % of males (p = 0.008). Stratifying by OSA severity, low AT was more prevalent in patients with mild disease, both in females and males. Among obese patients (Body Mass Index, BMI ≥30 kg/m2), low AT was present in 60.9 % of females compared to 24.3 % of males (p = 0.001). Our findings indicate that a low AT is significantly more prevalent in OSA females, remembering that our female population mainly corresponds to post-menopausal females. This may explain the more pronounced sleep fragmentation and neurobehavioral symptoms in women.